Lacourciere 2000

Methods	Country: Canada Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: No Follow‐up period: 12 months Loss to follow‐up: 11
Participants	Inclusion criteria DM: Type 2 diagnosed >/= 30 years of age Hypertension: Mild to moderate essential (sitting DBP 90‐115 mm Hg) AER: 20‐350 µg/min without evidence of UTI Losartan group Number: 52 Age: 59.2 (9.2) Sex (M/F): 39/13 Enalapril group Number: 51 Age: 57.8 (10.5) Sex (M/F): 44/7 Exclusion criteria Evidence or suspicion of renovascular disease History of malignant hypertension SBP > 210 mm Hg CVA in the previous 12 months or current transient Ischaemic attacks MI within the previous 12 months Clinically significant arteriovenous conduction disturbances and/or arrhythmias Unstable angina History of heart failure SCr ≥ 200 mmol/L Serum potassium ≥ 5.5 mmol/L or ≤ 3.5mmol/L Treatment with oral corticosteroid Concomitant use of agents that may affect BP except beta‐blockers and nitrates used in the treatment of stable angina Drug or alcohol abuse Pregnancy Breast feeding Ineffective contraception
Interventions	Losartan group 50 mg/d Enalapril group 5‐10 mg/d Co‐interventions Antihypertensive agents other than ACEi, AIIRA and CCB
Outcomes	BP AER GFR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear